Zimbabwe has turned down a major US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential data.
This rejection came to light after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesperson has since explained that the United States was seeking health data for research and commercial gain but refused to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to reach a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a similar case in Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
According to statements, 16 African countries have to date signed these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the end products would be accessible to our people if a future health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its push of one-on-one health agreements were disrupting structures already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent collaboration could be arranged in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it recognised the government's concerns, but urged that talks need to persist since a large portion of the nation's Aids initiatives depended on external financing.
"Where technical issues exist, including those involving data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
The situation highlights the ongoing debate between receiving vital international aid and protecting local interests in an ever more data-driven world.